Shai Mulinari
31 – 45 of 91
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
The will of Congress? Permissive regulation and the strategic use of labeling for the anti-influenza drug Relenza
(
- Contribution to journal › Article
-
Mark
Revisiting the pharmaceuticalisation of pandemic influenza using Lukes’ framework of power
(
- Contribution to journal › Article
-
Mark
Sociologiska perspektiv på coronakrisen : Fyra sociologer om samhällets reaktion på covid-19
(
- Contribution to journal › Letter
-
Mark
Bengt Olle Bengtsson intervjuad av Shai Mulinari : Om genetisk likhet och skillnad
(
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Ras i genetikens tidevarv
(
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Svenska gener? : Om stratifierad precisionsmedicin och genetikens etniska gränsdragningar
(
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Pharmaceutical lobbying and pandemic stockpiling : A feeling of déjà vu in the Nordic countries and why the sociological perspective is crucial to understand COVID-19
(
- Contribution to journal › Article
-
Mark
Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016)
(
- Contribution to journal › Article
-
Mark
Ras och genetiska skillnader : Introduktion till avsnittets texter
(
- Contribution to specialist publication or newspaper › Specialist publication article
-
Mark
Five years of pharmaceutical industry funding of patient organisations in Sweden: cross-sectional study of companies, patient organisations and drugs
2020) In PLoS ONE(
- Contribution to journal › Article
- 2019
-
Mark
Exposing drug industry funding of UK patient organisations
(
- Contribution to journal › Article
-
Mark
The whistleblowing drama behind Astellas’s suspension from the ABPI
(
- Contribution to journal › Letter
-
Mark
Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK
(
- Contribution to journal › Article
-
Mark
Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015
(
- Contribution to journal › Article
- 2018
-
Mark
Explaining biological depression theories
(
- Contribution to journal › Letter